BLVRA and metabolic dysfunction-associated steatohepatitis: BLVR-A protein levels and activation are significantly reduced in peripheral blood mononuclear cells from obese patients and are associated with impaired insulin signaling, obesity, metabolic syndrome, NASH and visceral adipose tissue inflammation, indicating that BLVR-A modulation could be a therapeutic approach to obesity prevention and care (187).